Exclusive: U.S. Cardinal Health puts $1.5 billion China business on block – sources

HONG KONG (Reuters) – U.S. drug distributor Cardinal Health has put its China business up for sale, drawing keen interest from state-backed Chinese pharmaceutical firms in a deal that may be worth up to $1.5 billion, sources familiar with the matter said.
( read original story …)